Agios Pharm Stock Performance
| AGIO Stock | USD 27.47 0.21 0.76% |
Agios Pharm has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.77, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Agios Pharm's returns are expected to increase less than the market. However, during the bear market, the loss of holding Agios Pharm is expected to be smaller as well. Agios Pharm right now shows a risk of 3.2%. Please confirm Agios Pharm jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if Agios Pharm will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Agios Pharm are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy forward indicators, Agios Pharm is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.76) | Five Day Return (6.34) | Year To Date Return 1.07 | Ten Year Return (42.44) | All Time Return (12.18) |
1 | Agios Pharmaceuticals, Inc. AGIO Shares Bought by HighVista Strategies LLC | 12/11/2025 |
2 | Disposition of 6000 shares by Cecilia Jones of Agios Pharm subject to Rule 16b-3 | 12/30/2025 |
3 | Disposition of 25528 shares by Goff Brian of Agios Pharm subject to Rule 16b-3 | 01/02/2026 |
4 | Acquisition by Gheuens Sarah of 2454 shares of Agios Pharm at 25.01 subject to Rule 16b-3 | 01/15/2026 |
5 | Acquisition by Capello Jeffrey D of 2120 shares of Agios Pharm subject to Rule 16b-3 | 02/03/2026 |
6 | Agios outlines path to profitability and targets 45M-50M in 2026 PK deficiency revenue as AQVESME U.S. launch progresses | 02/12/2026 |
7 | Agios Pharmaceuticals, Inc. Q4 2025 Earnings Call Transcript | 02/13/2026 |
8 | Research Analysts Offer Predictions for AGIO Q1 Earnings | 02/17/2026 |
9 | Sickle Cell Disease Competitive Landscape Report 2026 Comprehensive Analysis of Over 40 Companies and More Than 50 Drugs | 02/18/2026 |
10 | From Sizable Stake to Zero The Likely Reason Why Agios Shares Lost a 94 Million Backer | 02/23/2026 |
11 | Acquisition by Viswanadhan Krishnan of 14000 shares of Agios Pharm subject to Rule 16b-3 | 02/27/2026 |
12 | Disposition of 5272 shares by T Washburn of Agios Pharm at 28.88 subject to Rule 16b-3 | 03/03/2026 |
13 | Servier Boosts Presence in Rare Cancers With 2.5B Acquisition of Day One Biopharma | 03/06/2026 |
| Begin Period Cash Flow | 76.2 M | |
| Total Cashflows From Investing Activities | 377.2 M |
Agios Pharm Relative Risk vs. Return Landscape
If you would invest 2,728 in Agios Pharm on December 7, 2025 and sell it today you would earn a total of 19.00 from holding Agios Pharm or generate 0.7% return on investment over 90 days. Agios Pharm is currently generating 0.0587% in daily expected returns and assumes 3.2014% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Agios, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Agios Pharm Target Price Odds to finish over Current Price
The tendency of Agios Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 27.47 | 90 days | 27.47 | about 57.67 |
Based on a normal probability distribution, the odds of Agios Pharm to move above the current price in 90 days from now is about 57.67 (This Agios Pharm probability density function shows the probability of Agios Stock to fall within a particular range of prices over 90 days) .
Agios Pharm Price Density |
| Price |
Predictive Modules for Agios Pharm
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Agios Pharm. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Agios Pharm Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Agios Pharm is not an exception. The market had few large corrections towards the Agios Pharm's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Agios Pharm, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Agios Pharm within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | 0.77 | |
σ | Overall volatility | 1.24 | |
Ir | Information ratio | 0 |
Agios Pharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Agios Pharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Agios Pharm can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Agios Pharm had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 54.03 M. Net Loss for the year was (412.78 M) with loss before overhead, payroll, taxes, and interest of (291.85 M). | |
| Agios Pharm currently holds about 819.31 M in cash with (372.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from medcitynews.com: Servier Boosts Presence in Rare Cancers With 2.5B Acquisition of Day One Biopharma |
Agios Pharm Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Agios Stock often depends not only on the future outlook of the current and potential Agios Pharm's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Agios Pharm's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 58 M | |
| Cash And Short Term Investments | 854.4 M |
Agios Pharm Fundamentals Growth
Agios Stock prices reflect investors' perceptions of the future prospects and financial health of Agios Pharm, and Agios Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Agios Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (6.09) % | ||||
| Current Valuation | 837.5 M | ||||
| Shares Outstanding | 58.59 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 1.38 X | ||||
| Price To Sales | 30.02 X | ||||
| Revenue | 54.03 M | ||||
| Gross Profit | (291.85 M) | ||||
| EBITDA | (466.95 M) | ||||
| Net Income | (412.78 M) | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 62.02 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.98 X | ||||
| Book Value Per Share | 20.41 X | ||||
| Cash Flow From Operations | (372.98 M) | ||||
| Earnings Per Share | (6.99) X | ||||
| Market Capitalization | 1.62 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (561.71 M) | ||||
| Working Capital | 859.85 M | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
About Agios Pharm Performance
By examining Agios Pharm's fundamental ratios, stakeholders can obtain critical insights into Agios Pharm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Agios Pharm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.9 K | 2 K | |
| Return On Tangible Assets | (0.32) | (0.30) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.35) | (0.36) |
Things to note about Agios Pharm performance evaluation
Checking the ongoing alerts about Agios Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Agios Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Agios Pharm had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 54.03 M. Net Loss for the year was (412.78 M) with loss before overhead, payroll, taxes, and interest of (291.85 M). | |
| Agios Pharm currently holds about 819.31 M in cash with (372.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from medcitynews.com: Servier Boosts Presence in Rare Cancers With 2.5B Acquisition of Day One Biopharma |
- Analyzing Agios Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Agios Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Agios Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Agios Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Agios Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Agios Pharm's stock. These opinions can provide insight into Agios Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.99) | Revenue Per Share | Quarterly Revenue Growth 0.861 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.